Federated Hermes’s Maravai LifeSciences MRVI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.38M Buy
+1,094,265
New +$7.57M 0.01% 737
2024
Q1
– Sell
-44,807
Closed -$293K – 2100
2023
Q4
$293K Sell
44,807
-189,696
-81% -$1.23M ﹤0.01% 1456
2023
Q3
$2.35M Buy
234,503
+22,027
+10% +$242K 0.01% 874
2023
Q2
$2.64M Sell
212,476
-13,148
-6% -$177K 0.01% 869
2023
Q1
$3.16M Sell
225,624
-18,262
-7% -$262K 0.01% 813
2022
Q4
$3.49M Buy
243,886
+186,467
+325% +$2.94M 0.01% 761
2022
Q3
$1.47M Buy
57,419
+21,016
+58% +$527K ﹤0.01% 998
2022
Q2
$1.03M Buy
36,403
+36,036
+9,819% +$1.14M ﹤0.01% 1134
2022
Q1
$13K Sell
367
-23,360
-98% -$783K ﹤0.01% 1867
2021
Q4
$994K Sell
23,727
-63,614
-73% -$2.58M ﹤0.01% 1276
2021
Q3
$4.29M Buy
87,341
+37,599
+76% +$1.83M 0.01% 856
2021
Q2
$2.08M Buy
+49,742
New +$1.93M ﹤0.01% 1084
2021
Q1
– Sell
-20,000
Closed -$561K – 2311
2020
Q4
$561K Buy
+20,000
New +$557K ﹤0.01% 1497

Other funds holding MRVI

Federated Hermes's MRVI Position: Q3 2026 in Review

Federated Hermes opened a new position in Maravai LifeSciences (MRVI) in Q3 2026: 1,094,265 shares worth $8.38M. The stake represents 0.01% of the portfolio and ranks #737 among its holdings. This is a return to the name: Federated Hermes previously reported a position in MRVI as recently as Q4 2023.

Federated Hermes first reported a position in MRVI in Q4 2020 and has held it in 13 quarters since. 97 funds tracked by Wall St. Rank hold MRVI as of Q3 2026.

  • Federated Hermes held 1,094,265 shares of Maravai LifeSciences worth $8.38M as of Q3 2026.
  • Maravai LifeSciences was a new Federated Hermes position in Q3 2026.
  • Maravai LifeSciences made up 0.01% of Federated Hermes's portfolio in Q3 2026, its #737 holding.
  • Federated Hermes first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 13 quarters since.
  • 97 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2026.

Based on Federated Hermes's 13F filing for Q3 2026, filed 12 Nov 2026.